A new era of hope is emerging for those suffering from intestinal pseudo-obstruction as the market for treatment options is poised for explosive growth. According to Future Market Insights, the intestinal pseudo-obstruction treatment market is estimated to reach a valuation of US$ 23 billion by 2023-end, with a projected CAGR of 5%. This growth is expected to continue and escalate, reaching US$ 37 billion by 2033.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value in 2023 | US$ 23 billion |
| Projected Market Value in 2033 | US$ 37 billion |
| Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for intestinal pseudo-obstruction treatment is being driven by the growing geriatric population, which is particularly vulnerable to intestinal pseudo-obstruction due to age-related changes in the digestive system and other factors such as chronic diseases and weak immune systems. The prevalence of this condition is also rising due to factors such as sedentary lifestyles, unhealthy diets, and the increasing incidence of conditions such as diabetes and metabolic disorders that can lead to intestinal pseudo-obstruction.
The increasing awareness about the condition among patients and healthcare professionals is also driving the market, as people are becoming more informed about the symptoms and treatments available. This is leading to early diagnosis and better management of the condition, and is contributing to the growth of the market. The market is also being driven by the growing demand for minimally invasive surgical procedures. These procedures are becoming increasingly popular due to their low risk of complications, faster recovery times, and reduced costs compared to traditional surgical procedures. Some of the minimally invasive surgical procedures used to treat intestinal pseudo-obstruction include laparoscopic surgery, endoscopic procedures, and percutaneous procedures.
The rising demand for healthcare services in emerging markets, such as India and China, is also driving the market, as people in these countries become more aware of the condition and seek treatment for it. In addition, the increasing number of healthcare facilities and specialists in these countries is making it easier for people to access treatment for the condition, in turn fuelling market growth.
Principal Consultant
Intestinal pseudo-obstruction is a disorder caused by muscle or nerve problem which affects the movement of substances into the intestine. Intestinal pseudo-obstruction mimics the symptoms as those caused in the bowel.
Intestinal pseudo-obstruction can occur at any age but mostly affects older aged. Impairment of nerve, muscles or intestine cells of Cajal causes intestinal pseudo-obstruction disease.
Its symptoms can be abdominal pain, nausea, vomiting, constipation and bloating. Intestinal pseudo-obstruction can be diagnosed by colonoscopy, imaging studies, anorectal manometry, gastric emptying tests, blood test and biopsy. Intestinal pseudo-obstruction treatment includes nutritional support, Pharmacological therapy and in some cases surgery is preferred.
Prokinetics drugs like erythromycin, metoclopramide, domperidone and lubiprostone are the most prescribed drug in the Intestinal pseudo-obstruction treatment market. Another drug cisapride has been reported for a positive result but is currently available only in a few parts of the world. Over the last few years, many advances have been made to treat diagnose and treat intestinal pseudo-obstruction disorder.
Increasing prevalence of the gastrointestinal disease is expected to drive the Intestinal pseudo-obstruction treatment market. Rising cases of Parkinson’s disease, collagen vascular and others is expected to boost the intestinal pseudo-obstruction treatment market.
There are many infections which leads to Intestinal pseudo-obstruction disease, therefore increasing infectious disease is expected to drive the growth of the Intestinal pseudo-obstruction treatment market.
Cost-effective diagnosis and treatment also act as a driver in Intestinal pseudo-obstruction treatment market. As it mimics bowel, lack of awareness about the disorder can hamper the growth of the market Intestinal pseudo-obstruction treatment market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Based on drug class, antibiotics are expected to be the most preferred drug in the Intestinal pseudo-obstruction treatment market. Based on the route of administration, the oral route is the most frequently used route of drug administration in the Intestinal pseudo-obstruction treatment market.
Based on the distribution channel, retail pharmacies are expected to be the most profitable segment in the global Intestinal pseudo-obstruction treatment market.Over the last several decades, diagnosis and treatment of Intestinal pseudo-obstruction disorder have improved.
Many researchers are trying to study the role of the intestinal pacemaker, which follow the same principle of cardiac pacemakers. Early studies have improvements in vomiting and nausea condition in intestinal pseudo-obstruction disorder. As it requires many specialists, the disease has to be confirmed by several numbers of test.
Therefore, researches are conducted for developing new therapies for early diagnosis and treatment of intestinal pseudo-obstruction disorder. Scientists are studying the behavioural approach for pain management. It is reported that nutrition support is the mainstay in the management of intestinal pseudo-obstruction treatment, so management of nutrition has become the main focus of the market.
North America and Europe are expected to dominate the intestinal pseudo-obstruction treatment market, owing to the prominent technological advancements, innovations. High prevalence rates of chronic digestive disorder require patient diagnosing and treatment is expected to increase the growth of the Intestinal pseudo-obstruction market in these regions.
Increase in healthcare expenditure and also increasing population in developing region like Asia-Pacific is expected to further push intestinal pseudo-obstruction market growth for over the forecast period.
Some of the market participants in the global intestinal pseudo-obstruction treatment market identified across the value chain include:
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Drug Class 6.2. Administration 6.3. Distribution Channels 7. Global Market Analysis and Forecast, By Drug Class 7.1. Antibiotics 7.2. Antidepressants 7.3. Antidiarrheals 8. Global Market Analysis and Forecast, By Administration 8.1. Oral 8.2. Injectable 9. Global Market Analysis and Forecast, By Distribution Channels 9.1. Hospital Pharmacies 9.2. Retail Pharmacies 9.3. Drug Store 9.4. Online Sales 10. Global Market Analysis and Forecast, By Region 10.1. North America 10.2. Latin America 10.3. Western Europe 10.4. Asia Pacific 10.5. China 10.6. Japan 10.7. Middle East and Africa 11. North America Sales Analysis and Forecast, by Key Segments and Countries 12. Latin America Sales Analysis and Forecast, by Key Segments and Countries 13. Western Europe Sales Analysis and Forecast, by Key Segments and Countries 14. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries 15. China Sales Analysis and Forecast, by Key Segments and Countries 16. Japan Sales Analysis and Forecast, by Key Segments and Countries 17. Middle East and Africa Sales Analysis and Forecast, by Key Segments and Countries 18. Sales Forecast by Drug Class, Administration, and Distribution Channels for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 20. Company Profile 20.1. Dr. Reddy’s Laboratories Ltd. 20.2. Teva Pharmaceutical Industries Ltd. 20.3. GlaxoSmithKline plc 20.4. Abbott Laboratories 20.5. Pfizer Inc. 20.6. Johnson & Johnson 20.7. Callisto Pharmaceuticals Inc. 20.8. Biogen Inc. 20.9. Novartis A.G 20.10. Canila Healthcare Ltd
Explore Healthcare Insights
View Reports
Intestinal Pseudo-Obstruction Treatment Market
